RNTX · Rein Therapeutics, Inc.
$0.80
+0.00 (+0.00%)
At close · Aug 26
Market Cap
$69.01M
Shares
86.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.80
Open$0.81
Day$0.78–0.82
52W close$0.71–1.88
Avg vol 30d474K
Short int735K · 0.9% float · 2.2d
Short vol30%
DataNov 2022–Aug 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Nov 11, 2022; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−8%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−33%
trailing
YTD return
−31%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+28% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.85% of float · ▼ -16.0% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
59 holders — near 3-yr high, broad support
Squeeze score
40
elevated · 0–100
Fundamentals
EPS growth
+44%
Y/Y
Free cash flow
$-19.5M
Balance sheet
$3.2M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
8.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+28% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.85% of float · ▼ -16.0% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
59 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 7%
Range high $2
vs 200-day avg -32%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNTX
this stock
Rein Therapeutics, Inc.
|
$69.01M | -31.0% | — | — | 0.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Nov 11, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNTX | +1.0% | +5.5% | -32.8% | +8.5% | -31.0% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +1.4% | +0.5% | -45.2% | +5.9% | -43.4% |
Key facts
CIK
1420565
CUSIP
00887A204
13F (30d)
57 filings
56 filers
Visit website
Investor relations